In The News
-
GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides
FIERCE BIOTECH—GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides.
-
GSK to license Empirico’s COPD candidate for $85M upfront
ENDPOINTS NEWS—GSK said Tuesday it will spend $85 million upfront for an exclusive license to a Phase 1-stage small interfering RNA (siRNA) product being developed by Empirico to treat COPD.
-
GSK snaps up Empirico’s siRNA COPD asset in $745M deal
FIRSTWORD PHARMA—Aiming to further boost its oligonucleotide pipeline, GSK inked a licensing deal potentially worth up to $745 million for rights to Empirico’s EMP-012, an siRNA candidate in early clinical development for chronic obstructive pulmonary disease (COPD).
-
GSK strikes again, adding COPD candidate in $745m deal
PHARMAPHORUM—In its second pipeline-expanding deal in the space of 24 hours, GSK has licensed rights to a drug for chronic obstructive pulmonary disease (COPD) from US biotech Empirico for $85 million upfront.
-
GSK Expands Respiratory Pipeline With siRNA Pact
SCRIP–GSK is taking a bet on a small-interfering RNA (siRNA) gene silencing asset for lung disease in a new pact with Empirico. The US biotech specializes in siRNA therapies and GSK has acquired worldwide exclusive rights to its Phase I asset, EMP-012, for chronic obstructive pulmonary disease (COPD) via a $85m upfront deal.
-
GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD
MEDCITY NEWS—GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this prevalent lung disorder. The pharmaceutical giant is now adding one more to its pipeline, paying $85 million to secure rights to an early-stage drug that brings a novel approach to COPD.
-
GSK adds to COPD drug push with Empirico deal
BIOPHARMA DIVE—GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a “broad spectrum” of people with the chronic lung condition. Read the full article on the Biopharma Dive website >
-
Empirico Inks Drug Target Discovery Alliance With Antisense Drug Firm Ionis
GENOMEWEB—Empirico said on Thursday that it has formed a drug discovery alliance with antisense therapeutics firm Ionis Pharmaceuticals.
-
Empirico scores $660M deal with Ionis and lands a series A-2 fundraiser
BIOWORLD—It’s a big day for privately held Empirico Inc. as it embarks on a massive combo pharma deal with Ionis Pharmaceuticals Inc. while racking up a $12.5 million series A-2 financing.
-
Ionis finds new partner in a young biotech and its hopeful founder
ENDPOINTS NEWS—Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.